Accession Number : ADA329306

Title :   Evaluation of Drug and Vaccine Candidates in the Human Malaria/Aotus Monkey Model

Descriptive Note : Annual rept. 1 Mar 96-28 Feb 97

Corporate Author : PROMED TRADING S A MIAMI FL

Personal Author(s) : Odaldia, Nicanor

PDF Url : ADA329306

Report Date : MAR 1997

Pagination or Media Count : 26

Abstract : Chloroquine resistance (CQR) of the AMRU-1 Strain of Plasmodium vivax was not reversed in Aotus using prochlorperazine and chloroquine alone or in combination during a seven day regimen. An AMA-1 erythrocytic DNA vaccine, partially protected 1/3 monkeys, which showed a low grade parasitemia that ended in treatment due to a 40% reduction in hematocrit (Hto). After rechallenge, all monkeys except for one that selfcured, had to be treated 22-29 days post inoculation (PI) due to their low Htos. An EBA-1 DNA erythrocytic vaccine offered partial protection in 1/3 monkeys that self cured 21 days PI. Multiple rechallenges with the FVO strain yielded sterile immunity. The effectiveness of the intradermal (ID) route of inoculation Vs the IM route at inducing high levels of antibodies in Aotus was confirmed when a distinct antigenic DNA vaccine such as HsBAg was used. The addition of Oligonucleotides to the vaccine formulation greatly increased the antibody responses observed with this antigen.

Descriptors :   *MALARIA, *VACCINES, DEOXYRIBONUCLEIC ACIDS, ANTIBODIES, DRUGS, SPOROZOITES, INOCULATION, IMMUNITY, PLASMODIUM FALCIPARUM, ANTIGENS, OLIGOMERS, RESISTANCE(BIOLOGY), MONKEYS, PARASITEMIAS, NUCLEOTIDES, CHLOROQUINE, PLASMODIUM VIVAX.

Subject Categories : Medicine and Medical Research
      Pharmacology

Distribution Statement : APPROVED FOR PUBLIC RELEASE